東北大学大学院 医学系研究科 緩和医療学分野

研究案内

HOME        研究案内        論文

研究案内

論文・書籍・受賞などの実績

2017年

  1. Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M: Three-year Follow-up of an Alectinib Phase 1/2 study in ALK-positive Non-Small-Cell Lung Cancer: AF-001JP. J Clin Oncol 2017; 35: 1515-21.
  2. Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H: A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Investig New Drug 2017; 35: 227-34.
  3. Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M: Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Sci 2017; 108: 1263-70.
  4. Miyauchi E, Ichinose M, Inoue A: Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease. J Thorac Oncol 2017; 12: e59-e61.
  5. Miyauchi E, Inoue A, Usui K, et al.: Phase II study of modified carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer: North Japan Lung Cancer Study Group Trial 1301. Oncologist 2017; 6: 640-e59.
  6. Tominaga M, Okamoto M, Kawayama T, Matsuoka M, Kaieda S,MD, Sakazaki Y, Kinoshita T, Mori D, Inoue A, Hoshino T: Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis. Respirat Investig 2017: 55; 293-9.
  7. Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H: Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2017; 2: e000214.
  8. Kosugi K, Tagami K, Tanimoto T: Trial of Pregabalin for Acute and Chronic Sciatica. N Engl J Med. 2017 Jun 15;376(24):2396.
  9. Kako J, Kobayashi M, Kanno Y, Tagami K: Intranasal Vinegar as an Effective Treatment for Persistent Hiccups in a Patient With Advanced Cancer Undergoing Palliative Care. J Pain Symptom Manage. 2017 Aug;54(2):e2-e4.
  10. Takahashi K, Proshin S, Yamaguchi K,Yamashita, R. Katakura, K. Yamamoto, H. Shima, M. Hosono, Taeko Miyagi: Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. BBA General Subjects. 2017; 1861: 2778-88.

2016年

  1. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M : Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A Retrospective Analysis for 1,660 Japanese patients. Jpn J Clin Oncol. 2016; 45: 462-7.
  2. Takeuchi K, Togashi Y, Kamihira Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T : Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016; 27: 185-92.
  3. Shiono M, Huang K, Downey R, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk A, Inoue A, Halmos B, Acharyya S : The association between metastasis and cachexia in lung cancer. Cancer Med. 2016; 5: 2641-8.
  4. Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K : A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 2016; 99: 131-6.
  5. Scagliotti G, Nishio M, Satouchi M, Valmadre G, Niho S, Galetta D, Cortinovis D, Benedetti F, Yoshihara E, Makris L, Inoue A, Kubota K : Phase 2 randomized study of TAS-102 versus topotecan oramrubicin in patients requiring second-line chemotherapy for smallcell lung cancer refractory or sensitive to frontline platinum-basedchemotherapy. Lung Cancer. 2016; 100: 20-23.
  6. Nakajima N, Abe Y : Concurrent specialized palliative care upon initiation of first-line chemotherapy for cancer progression:Is it early enough? Am J Hosp Palliat Med. 2016; 33: 340-345.
  7. Nakajima N: Characteristics of oral problems and effects of oral care in terminally ill patients in cancer. Am J Hosp Palliat Med. 2016; 22 Feb: [Epub ahead of print]
  8. Higashiguchi T, Ikegaki J, Sobue K, Tamura Y, Nakajima N, Futamura A, Miyashita M, Mori N, Inui A, Ohta K, Hosokawa T : Guidelines for parenteral fluid management for terminal cancer patients. Jpn J Clin Oncol. 2016; 12 Aug: [Epub ahead of print]
  9. Hamano J, Yamaguchi T, Maeda I, Suga A, Hisanaga T, Ishihara T, Iwashita T, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Morita T: Multicenter cohort study on the survival time of cancer patients dying at home or in a hospital. Cancer. 2016; 122: 1453-1460.
  10. Miyagi T: Glycosignals in Cancer : Differential roles of mammalian sialidases in cancers. (Eds by Furukawa K, and Fukuda M), Springer 2016 ; 35-53.
  11. 中島信久: がん終末期の口腔ケア-口腔乾燥の現状と全人的苦痛の視点からみた問題点-.日本口腔ケア学会雑誌2016; 11: 19-23.

2015年

  1. Watanabe S, Inoue A, Nukiwa T, Kobayashi K. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion. Anticancer Res 2015; 35: 6957-61.
  2. Ishimoto O, Sugawara S, Inoue A, Maemondo M, Nukiwa T. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study. Respir Investig 2015; 53: 156-60.
  3. Inoue A, Sugawara S, Maemondo M, et al. Randomized Phase II Trial Comparing Amrubicin with Re-challenge of Platinum Doublet in Patients with Sensitive-Relapsed Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0702. Lung Cancer 2015; 89: 61-5.
  4. Nakajima N, Kusumoto K, Onishi H, Ishida M. Does the Approach of Disclosing More Detailed Information of Cancer for the Terminally Ill Patients Improve the Quality of Communication Involving Patients, Families, and Medical Professionals? Am J Hosp Palliat Care 2015; 32: 776-82.
  5. Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Ono S, Ozawa T, Yamamoto R, Tsuneto S. Independent validation of the modified prognosis palliative care study predictor models in three palliative care settings. J Pain Symptom Manage 2015; 49: 853-60.
  6. Miura T, Matsumoto Y, Hama T, Amano K, Tei Y, Kikuchi A, Suga A, Hisanaga T, Ishihara T, Abe M, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Morita T, Kinoshita H. Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study. Support Care Cancer 2015; 23: 3149-56.
  7. Takahashi K, Hosono M, Sato I, Hata K, Wada T, Yamaguchi K, Nitta K, Shima H, Miyagi T. Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling. Int J Cancer 2015; 137:1560-73.
  8. Shiozaki K, Takahashi K, Hosono M, Yamaguchi K, Hata H, Shiozaki M, Bassi R, Prinetti A, Sonnino S, Nitta K, Miyagi T. Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration. FASEB J 2015; 29: 2099-111.
  9. Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opin Pharmacother 2015; 16: 465-72.
  10. Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa TRandomized Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-small Cell Lung Cancer with Sensitive EGFR Mutations: NEJ005/TCOG0902. Ann Oncol 2015; 26: 888-94.
  11. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol 2015;33:1958-65
  12. Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. Lung Cancer 2015; 88: 181-6.
  13. Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation positive advanced non-small cell lung cancer - data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol 2015; 45: 670-6.
  14. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 2015; 26: 1401-8.
  15. Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res 2015; 35: 5797-806.
  16. Nakajima N, Kusumoto K, Onishi H, Ishida M: Does the approach of disclosing more detailed information of cancer for the terminally ill patients improve the quality of communication involving patients, families, and medical professionals? Am J Hosp Palliat Care. 2015; Nov32(7): 776-782.

2014年

  1. Nakajima N, Satake N, Nakaho T. Indications and practice of artificial hydration for terminally ill cancer patients. Curr Opin Support Palliat Care 2014; 8: 358-63.
  2. Nakajima N, Takahashi Y, Ishitani K. The volume of hydration in terminally ill cancer patients with hydration-related symptoms: a prospective study. J Palliat Med 2014; 17: 1037-41.

2013年

  1. Nakajima N, Hata Y, Onishi H, Ishida M The Evaluation of the Relationship Between the Level of Disclosure of Cancer in Terminally Ill Patients With Cancer and the Quality of Terminal Care in These Patients and Their Families Using the Support Team Assessment Schedule. American Journal of Hospice and Palliative Medicine  30:370-376,2013
  2. Nakajima N, Hata Y, Kusumoto K. A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013; 16: 185-9.

2012年

  1. Yamaguchi T, Morita T, Shinjo T, Inoue S, Takigawa C, Aruga E, Tani K, Hara T, Tamura Y, Suga A, Adachi S, Katayama H, Osaka I, Saito Y, Nakajima N, Higashiguti T, Hayashi T, Okabe T, Kohara H, Tamaki T, Chinone Y, Aragane H, Kanai Y, Tokura N, Yamaguchi T, Asada T, Uchitomi Y Effect of Parenteral Hydration Therapy Based on the Japanese National Clinical Guideline on Quality of Life, Discomfort, and Symptom Intensity in patients with Advanced Cancer  Journal of Pain and Symptom Management 43:1001-1012,2012

2008年

  1. Tei Y, Morita T, Nakaho T, Takigawa C, Higuchi A, Suga A, Tajima T, Ikenaga M, Higuchi H, Shimoyama N, Fujimoto M. Treatment efficacy of neural blockade in specialized palliative care services in Japan: a multicenter audit survey. J Pain Symptom Manage. 2008 Nov;36(5):461-7.

2007年

  1. Kikuchi N, Ohmori K, Kuriyama S, Shimada A, Nakaho T, Yamamuro M, Tsuji I. Survival prediction of patients with advanced cancer: the predictive accuracy of the model based on biological markers. J Pain Symptom Manage. 2007 Dec;34(6):600-6.

東北大学病院 緩和医療学分野のページ

東北大学病院 緩和医療学分野のページ

Page Top

Copyright(C) 東北大学大学院 医学系研究科 緩和医療学分野 All Rights Reserved.